COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situ

Abstract

Background: In women with duct carcinoma in-situ (DCIS) receiving breast conservation therapy (BCT), in-breast recurrences are seen in approximately 10%, but cannot be accurately predicted using clinical and histological criteria. We performed a case-control study to identify protein markers of local recurrence risk in DCIS.

Vitamin E-modulated gene expression associated with ROS generation

“…Similarly, 15-deoxy-delta (12,14)-prostaglandin J2 (15d-PGJ2), a natural PPARc activator, and troglitazone decrease COX-2 expression in human monocyte leukemia cells in vitro, resulting in apoptosis of the cancer cells (Liu et al, 2007). Kulkarni et al's study suggests an inverse relationship between expression of COX-2 and PPARc and the potential uses of COX-2 and PPARc expression as biological markers in cancer studies (Kulkarni et al, 2008).…”

Biology of DCIS and Progression to Invasive Disease

“…Abrogation of the Rb pathway has recently been proposed as a mechanism by which DCIS can survive the hypoxic and stressful intraductal environment (Espina and Liotta 2011). Approximately 70, 60, and 35 % of DCIS lesions are Rb+, cyclin D1+, and p16+, respectively (Gauthier et al 2007;Millar et al 2007;Kulkarni et al 2008;Okumura et al 2008;Kerlikowske et al 2010), while 22 % are both p16+/Ki-67+ (Bose et al 2006). PTEN loss has also been linked to the basal subtype of DCIS (Polyak 2010).…”

Inflammation and breast cancer

“…Kulkarni et al conducted a case-control study of women who had undergone breastconserving therapy for DCIS, 31 of whom had relapsed, and 38 controls who were disease free [93]. Immunohistochemical assessment of ER, PR, HER2/neu, cyclin D1, p53, p21, COX-2 and PPARg was performed.…”